Allopregnanolone and Progesterone in Experimental Neuropathic Pain: Former and New Insights with a Translational Perspective

Cell Mol Neurobiol. 2019 May;39(4):523-537. doi: 10.1007/s10571-018-0618-1. Epub 2018 Sep 5.

Abstract

In the last decades, an active and stimulating area of research has been devoted to explore the role of neuroactive steroids in pain modulation. Despite challenges, these studies have clearly contributed to unravel the multiple and complex actions and potential mechanisms underlying steroid effects in several experimental conditions that mimic human chronic pain states. Based on the available data, this review focuses mainly on progesterone and its reduced derivative allopregnanolone (also called 3α,5α-tetrahydroprogesterone) which have been shown to prevent or even reverse the complex maladaptive changes and pain behaviors that arise in the nervous system after injury or disease. Because the characterization of new related molecules with improved specificity and enhanced pharmacological profiles may represent a crucial step to develop more efficient steroid-based therapies, we have also discussed the potential of novel synthetic analogs of allopregnanolone as valuable molecules for the treatment of neuropathic pain.

Keywords: Allopregnanolone; Dorsal root ganglia; Mitochondria; Neuroactive steroids; Neuropathic pain; Neurosteroids; Progesterone; Spinal cord.

Publication types

  • Review

MeSH terms

  • Animals
  • Humans
  • Models, Biological
  • Neuralgia / drug therapy
  • Neuralgia / metabolism*
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use
  • Pregnanolone / biosynthesis
  • Pregnanolone / metabolism*
  • Progesterone / biosynthesis
  • Progesterone / chemistry
  • Progesterone / metabolism*
  • Translational Research, Biomedical*

Substances

  • Neuroprotective Agents
  • Progesterone
  • Pregnanolone